Loading

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support

PeerCurrent

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Drug or technology

Retlirafusp alfa+TP-AC

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials1 Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 7, 2026 · PHASE 2 TRIAL

Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer

ClinicalTrials.gov

Phase 2 interventional trial in planning stage with no posted results; early-phase design studying a novel immunotherapy combination in TNBC.

PreliminaryRetlirafusp alfa+TP-AC Triple Negative Breast Cancer (TNBC)Retlirafusp alfa+Nab-paclitaxel:

Reported

Planned enrollment120

Phase2

Primary outcome (Late-Stage Cohor…Objective Response Rate

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support